ArticleSurgical endoscopy2025
Feasibility and safety of endoscopic resection for cardial submucosal tumors more than 30 mm in diameter.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Third-space endoscopy: Current techniques, clinical applications, and future directions.The Journal of international medical research · 2026Review
- A pilot study on the application and efficacy of mucosal traction-assisted clip closure in endoscopic full-thickness resection for gastric submucosal tumors.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsEndoscopic resection has emerged as a viable option for cardial submucosal tumors (SMTs), but existing evidence remains limited by small sample sizes. This study aimed to evaluate the efficacy and safety of endoscopic resection techniques for cardial SMTs more than 30 mm in diameter.
methodsBetween January 2012 and October 2024, 107 patients with cardial SMTs larger than 30 mm were included in this study. Data on patient characteristics, clinical outcomes, and follow-up were retrospectively analyzed.
resultsAmong 107 patients, 42 patients underwent submucosal tunneling endoscopic resection (STER), 34 patients underwent endoscopic full-thickness resection (EFTR), and 31 patients received endoscopic submucosal dissection (ESD). The mean lesion size was 4.2 ± 1.9 cm. The rate of en bloc resection and complete resection were 94.3% and 91.6%, respectively. Postoperative adverse events included delayed bleeding (2 cases), delayed perforation (2 cases), subcutaneous emphysema (2 cases) and pleural effusion (2 cases). One case of recurrence was detected during the mean follow-up period of 37.4 ± 22.5 months. Multivariate analysis showed irregular morphology (OR 2.076, 95% CI 0.513-6.274, P = 0.039) and invasion into the muscularis propria layer (OR 6.157, 95% CI1.160-7.602, P = 0.031) were independent risk factors for incomplete resection; lesion size ≥ 40 mm (OR 6.271, 95% CI 1.024-7.856, P = 0.027), irregular morphology (OR 4.734, 95% CI 1.489-6.052, P = 0.042), trans-cardia tumor (OR 5.526, 95% CI 1.160-7.602, P = 0.043) and invasion into the muscularis propria layer (OR 5.104, 95% CI 1.893-7.965, P = 0.030) were independent risk factors for long operative times.
conclusionEndoscopic resection is an effective and safe treatment for cardial SMTs larger than 30 mm, particularly when performed by experienced endoscopists. Long-term surveillance remains crucial for early detection of recurrence.
Indexed as
Identifiers
40954378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.